rLVS(delta) capB/Yp F1-V single vector platform vaccine expressing Yersinia pestis F1 and LcrV antigens provides complete protection against lethal respiratory challenge with virulent plague bacilli

By sjmartinez • May 27, 2025

Jia Q, Bowen RA, Masleša-Galić S, Horwitz MA. rLVS ΔcapB/Yp F1-V single vector platform vaccine expressing Yersinia pestis F1 and LcrV antigens provides complete protection against lethal respiratory challenge with virulent plague bacilli. Hum Vaccin Immunother. 2025 Dec;21(1):2507475. doi: 10.1080/21645515.2025.2507475. Epub 2025 May 26. PMID: 40417828.

Tags: bioterrorism, F1, Francisella tularensis, Infectious Diseases, LcrV, LVS ΔcapB, plague, Publications, single vector platform vaccine, Tier 1 select agent, vaccine, Yersinia pestis

Related Posts

Study design and procedures for a hybrid effectiveness-implementation incomplete stepped-wedge cluster-randomized trial to evaluate a differentiated point-of-care HIV diagnosis and management model for the prevention of vertical transmission of HIV in Malawi: The PAC-Man trial protocol

Herce ME, Cassidy C, Munson A, Edwards JK, Rutstein SE, Matoga M, Kumwenda C, Simon KR, van Oosterhout JJ, Cox CM, Kamanga F, Kumwenda W,[...]

Prevalence of chlamydial, gonococcal and syphilis positivity by anatomical site and sex via self-collected biospecimens using at-home testing kits among a large and diverse cohort of men and women enrolled in the MACS/WIHS Combined Cohort Study (MWCCS) in the USA

Mimiaga MJ, Tian J, Chiu I, Yonko EA, Noori G, Aziz N, Jamieson BD, Qian Y, Alcaide ML, Augenbraun M, Friedman MR, Kempf MC, Dionne-Odom[...]

Type 2 immune responses are associated with less severe COVID-19 in a hospitalized cohort

Jayavelu ND, Qi J, Milliren CE, Ozonoff A, Liu S, Levy O, Baden LR, Melamed E, McComsey GA, Cairns CB, Schaenman J, Shaw AC, Hafler[...]